Nemolizumab Approved for AD, Prurigo Nodularis in Europe

The medication, also approved in the United States, is the first approved monoclonal antibody that specifically blocks the signaling of interleukin (IL)-31.
Medscape Medical News

source https://www.medscape.com/viewarticle/european-commission-approves-nemolizumab-atopic-dermatitis-2025a100048f?src=rss

Comments

Popular posts from this blog

RA and RA-ILD Linked to Higher Lung Cancer Risk

DC’s Harllee Harper Is Using Public Health Tools to Prevent Gun Violence. Will It Work?